News
ROTTERDAM (the Netherlands), SAN DIEGO (US), GHENT (Belgium), December 22, 2021: Today, SkylineDx announced a 3-year strategic partnership with life sciences institute VIB for the evaluation and initiation of collaborative projects focused on...
ROTTERDAM (the Netherlands), SAN DIEGO (USA), December 21, 2021: today, SkylineDx announced it received a capital investment from USA based investment and advisory firm Novalis LifeSciences, and one of Benelux’ largest biotech investors...
ROTTERDAM (the Netherlands), SAN DIEGO (California, US), November 9, 2021: today, SkylineDx announced that the Accreditation Committee of the College of American Pathologists (CAP) has renewed accreditation to SkylineDx’ laboratory in San Diego, California...
ROTTERDAM (the Netherlands), SAN DIEGO (US), October 12, 2021: today, SkylineDx announced it has entered into an exclusive patent license agreement with Imperial College London for the worldwide development and commercialization of a...
ROTTERDAM (the Netherlands), SAN DIEGO (US), June 24, 2021: Today, SkylineDx announced to invest in research and development in the field of Squamous Cell Carcinoma (SCC), as part of a Dutch consortium including...
ROTTERDAM (the Netherlands), SAN DIEGO (US), June 10, 2021: Today, SkylineDx announced that the first hospitals will start including melanoma patients in a large prospective clinical study in the United States, to validate...
ROTTERDAM (the Netherlands), SAN DIEGO (US), April 30, 2021: SkylineDx announced that the performance of their melanoma diagnostic test (Merlin Assay) is confirmed in an independent group of U.S. patients from the Mayo...
ROTTERDAM (the Netherlands), SAN DIEGO (US), April 22, 2021: SkylineDx and Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announce the signing of a new partnership agreement which targets...
ROTTERDAM (the Netherlands), SAN DIEGO (US), March 23, 2021: SkylineDx received the first Merlin Assay clinical test requests and therefore reported initial gross sales ahead of the commercial launch at the World Congress...
ROTTERDAM (The Netherlands) and SAN DIEGO (US), February 23, 2021: today, SkylineDx announces to have signed a license agreement with Oncode Institute and Utrecht Holdings on a shared patent covering the innovative algorithm...
ROTTERDAM (the Netherlands) and SAN DIEGO (US), February 18, 2021: today, SkylineDx announced that it received the esteemed ISO 13485:2016 Quality Management System certificate from notified body BSI Netherlands, after their successful audit...
ROTTERDAM (the Netherlands) and SAN DIEGO (US), February 15, 2021: today, SkylineDx announced a research collaboration with an academic hospital and a Dutch cancer registry to investigate patients with early-stage melanoma (skin cancer)...
ROTTERDAM (the Netherlands), SAN DIEGO (US), LONDON (UK), September 10, 2020: SkylineDx, announces a collaboration agreement with Professor Michael Levin’s group at Imperial College London and Professor Jane Burns’ group at University of...
ROTTERDAM (the Netherlands) and SAN DIEGO (US), August 26, 2020: SkylineDx signed a collaboration agreement with a multi-disciplinary clinical consortium in the Netherlands that designed a trial to implement a diagnostic innovation to...
ROTTERDAM (the Netherlands) and SAN DIEGO (US), June 23, 2020: last week, SkylineDx signed the 10th collaboration agreement with an academic partner for research under the extensive Falcon R&D Program to further validate...
ROTTERDAM (the Netherlands) and SAN DIEGO (US), May 14, 2020: SkylineDx announces the publication of two ASCO abstracts describing a biomarker that identifies a subgroup of skin cancer (cutaneous melanoma) patients that could...
ROTTERDAM (the Netherlands) and SAN DIEGO (US), May 12, 2020: Everything Genetic Ltd has partnered with a leading private health insurance company in the UK to design an access strategy for patients with...
ROTTERDAM (the Netherlands) and SAN DIEGO (US), April 22, 2020: SkylineDx announced today that the Merlin Assay for melanoma is officially added to their test menu and available as Laboratory Developed Test from...
